Background : The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the related disease (COVID-19) has rapidly spread to a pandemic proportion, increasing the demands on health systems for the containment and management of COVID-19. Nowadays, one of the critical issues still to be pointed out regards COVID-19 treatment regimens and timing: which drug, in which phase, for how long? Methods : Our narrative review, developed using MEDLINE and EMBASE, summarizes the main evidences in favor or against the current proposed treatment regimens for COVID-19, with a particular focus on antiviral agents. Results: Although many agents have been proposed as possible treatment, to date, any of the potential drugs against SARS-CoV-2 has shown to be safe and effective for treating COVID-19. Despite the lack of definitive evidence, remdesivir remains the only antiviral with encouraging effects in hospitalized patients with COVID-19. Conclusions : In such a complex moment of global health emergency, it is hard to demand scientific evidence. Nevertheless, randomized clinical trials aiming to identify effective and safe drugs against SARS-CoV-2 infection are urgently needed in order to confirm or reject the currently available evidence.
【저자키워드】 COVID-19, antiviral therapy, management, early phase, current evidences, current recommendations, 【초록키워드】 Treatment, SARS-CoV-2, randomized clinical trial, coronavirus, pandemic, Antiviral, SARS-COV-2 infection, Infection, Remdesivir, drug, outbreak, Antiviral agents, health system, disease, Critical, Evidence, Safe, health emergency, acute respiratory syndrome, complex, favor, treatment regimen, treating COVID-19, Effect, effective, shown, identify, lack, spread to, proportion, hospitalized patient, with COVID-19, 【제목키워드】 review, Strategy, phase, focus, narrative, Potential,